Neuland Laboratories To Invest $20 Million In Process Development And Kilo Lab Facility At Genome Valley, Hyderabad
Neuland Laboratories, a contract development and manufacturing organisation (CDMO) focused on complex active pharmaceutical ingredients (APIs), will invest $20 million to establish a dedicated process development laboratory and integrated kilo lab at its Genome Valley campus in Hyderabad. The 135,000 sq ft facility will be commissioned in phases, with full completion targeted by October 2026.
The company is using an existing building for the project, meaning the entire $20 million outlay will go toward specialist fit-out rather than shell construction. Once complete, the facility will expand Neuland's process development workforce to more than 500 scientists.
The site will include five peptide laboratories, three purification laboratories, and dedicated zones for process engineering, polymorph studies, process safety and advanced flow chemistry. The integrated kilo lab will be equipped with 20-litre to 250-litre all-glass reactors, cryogenic processing capability and multiple filtration systems, intended to bridge laboratory-scale research and commercial manufacturing.
The facility will also incorporate non-GMP kilo labs, AI-driven route scouting, parallel synthesis and electronic laboratory notebooks, aimed at enabling earlier manufacturability insight and reducing redundant testing during scale-up.
Neuland operates existing manufacturing units at Bonthapally and Pashamylaram in Telangana and is separately commissioning a new commercial-scale peptide manufacturing facility at its Bonthapally campus. The company exports to more than 80 countries and holds regulatory approvals including US FDA, EDQM and Japan's PMDA.